Current Pharmaceutical Analysis, Год журнала: 2024, Номер 21(1), С. 33 - 43
Опубликована: Дек. 1, 2024
Язык: Английский
Biomolecules, Год журнала: 2022, Номер 12(8), С. 1021 - 1021
Опубликована: Июль 23, 2022
Molecular cancer biomarkers are any measurable molecular indicator of risk cancer, occurrence or patient outcome. They may include germline somatic genetic variants, epigenetic signatures, transcriptional changes, and proteomic signatures. These indicators based on biomolecules, such as nucleic acids proteins, that can be detected in samples obtained from tissues through tumor biopsy or, more easily non-invasively, blood (or serum plasma), saliva, buccal swabs, stool, urine, etc. Detection technologies have advanced tremendously over the last decades, including techniques next-generation sequencing, nanotechnology, methods to study circulating DNA/RNA exosomes. Clinical applications extensive. used tools for assessment, screening early detection accurate diagnosis, prognosis, prediction response therapy, surveillance monitoring response. Therefore, they help optimize making decisions clinical practice. Moreover, precision oncology is needed newly developed targeted therapies, functional only patients with specific mutations, identification these subsets patients. Improvement field is, however, overcome scientific challenge developing new greater sensitivity, specificity, positive predictive value.
Язык: Английский
Процитировано
273
Journal of Translational Medicine, Год журнала: 2023, Номер 21(1)
Опубликована: Фев. 11, 2023
Abstract Cancer is a worldwide pandemic. The burden it imposes grows steadily on global scale causing emotional, physical, and financial strains individuals, families, health care systems. Despite being the second leading cause of death worldwide, many cancers do not have screening programs people with high risk developing cancer fail to follow advised medical regime due nature available tests other challenges compliance. Moreover, liquid biopsy strategies developed for early detection lack sensitivity required detect early-stage cancers. Early key improved quality life, survival, reduce treatments which are greater at later stage detection. This review examines current market, focusing in particular strengths drawbacks techniques achieving We explore clinical utility technologies earlier solid cancers, focus how combination various spectroscopic -omic methodologies may pave way more efficient diagnostics.
Язык: Английский
Процитировано
174
Cancers, Год журнала: 2023, Номер 15(5), С. 1579 - 1579
Опубликована: Март 3, 2023
Cancer is among the leading causes of death worldwide. Early diagnosis and prognosis are vital to improve patients’ outcomes. The gold standard tumor characterization tissue biopsy. Amongst constraints biopsy collection sampling frequency incomplete representation entire bulk. Liquid approaches, including analysis circulating cells (CTCs), DNA (ctDNA), miRNAs, tumor-derived extracellular vesicles (EVs), as well certain protein signatures that released in circulation from primary tumors their metastatic sites, present a promising more potent candidate for patient follow up monitoring. minimally invasive nature liquid biopsies, allowing frequent collection, can be used monitoring therapy response real time, development novel approaches therapeutic management cancer patients. In this review we will describe recent advances field markers focusing on advantages disadvantages.
Язык: Английский
Процитировано
70
Molecular & Cellular Proteomics, Год журнала: 2023, Номер 22(7), С. 100577 - 100577
Опубликована: Май 19, 2023
Accurate biomarkers are a crucial and necessary precondition for precision medicine, yet existing ones often unspecific new have been very slow to enter the clinic. Mass spectrometry (MS)-based proteomics excels by its untargeted nature, specificity of identification, quantification, making it an ideal technology biomarker discovery routine measurement. It has unique attributes compared affinity binder technologies, such as OLINK Proximity Extension Assay SOMAscan. In in previous review 2017, we described technological conceptual limitations that had held back success. We proposed 'rectangular strategy' better separate true minimizing cohort-specific effects. Today, this converged with advances MS-based technology, increased sample throughput, depth quantification. As result, studies become more successful, producing candidates withstand independent verification and, some cases, already outperform state-of-the-art clinical assays. summarize developments over last years, including benefits large cohorts, which acceptance. Shorter gradients, scan modes, multiplexing about drastically increase cross-study integration, proxies absolute levels. found multiprotein panels inherently robust than current single analyte tests capture complexity human phenotypes. Routine MS measurement clinic is fast becoming viable option. The full set proteins body fluid (global proteome) most important reference best process control. Additionally, increasingly all information could be obtained from targeted analysis although latter may straightforward way regular use. Many challenges remain, not least regulatory ethical but outlook applications never brighter.
Язык: Английский
Процитировано
65
Clinical Proteomics, Год журнала: 2023, Номер 20(1)
Опубликована: Авг. 26, 2023
Abstract Mass spectrometry (MS)-based proteomics have been increasingly implemented in various disciplines of laboratory medicine to identify and quantify biomolecules a variety biological specimens. MS-based is continuously expanding widely applied biomarker discovery for early detection, prognosis markers treatment response prediction monitoring. Furthermore, making these advanced tests more accessible affordable will the greatest healthcare benefit. This review article highlights new paradigms clinical has created microbiology laboratories, cancer research diagnosis metabolic disorders. The technique preferred over conventional methods disease detection therapy monitoring its combined advantages multiplexing capacity, remarkable analytical specificity sensitivity low turnaround time. Despite achievements development adoption number practices, are expected undergo transition from bench bedside near future. provides insights trials recent progresses (mainly covering literature NCBI database) application laboratories.
Язык: Английский
Процитировано
63
Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)
Опубликована: Март 22, 2024
Abstract Cancer early detection and treatment response prediction continue to pose significant challenges. liquid biopsies focusing on detecting circulating tumor cells (CTCs) DNA (ctDNA) have shown enormous potential due their non-invasive nature the implications in precision cancer management. Recently, biopsy has been further expanded profile glycoproteins, which are products of post-translational modifications proteins play key roles both normal pathological processes, including cancers. The advancements chemical mass spectrometry-based technologies artificial intelligence-based platforms enabled extensive studies organ-specific changes glycans glycoproteins through glycomics glycoproteomics. Glycoproteomic analysis emerged as a promising tool for biomarker discovery development cancers efficacy immunotherapies. These biomarkers could crucial role aiding intervention personalized therapy decisions. In this review, we summarize advance glycoproteomic promise challenges integration into clinical practice improve patient care.
Язык: Английский
Процитировано
26
Chemical Reviews, Год журнала: 2024, Номер 124(20), С. 11242 - 11347
Опубликована: Окт. 9, 2024
Biopsy, including tissue and liquid biopsy, offers comprehensive real-time physiological pathological information for disease detection, diagnosis, monitoring. Fluorescent probes are frequently selected to obtain adequate on processes in a rapid minimally invasive manner based their advantages biopsy. However, conventional fluorescent have been found show aggregation-caused quenching (ACQ) properties, impeding greater progresses this area. Since the discovery of aggregation-induced emission luminogen (AIEgen) promoted advancements molecular bionanomaterials owing unique high quantum yield (QY) signal-to-noise ratio (SNR),
Язык: Английский
Процитировано
17
Medicinal Research Reviews, Год журнала: 2025, Номер unknown
Опубликована: Янв. 9, 2025
ABSTRACT Proteins hold pivotal importance since many diseases manifest changes in protein activity. Proteomics techniques provide a comprehensive exploration of structure, abundance, and function biological samples, enabling the holistic characterization overall organisms. Nowadays, breadth emerging methodologies proteomics is unprecedentedly vast, with constant optimization technologies sample processing, data collection, analysis, its scope application steadily transitioning from bench to clinic. Here, we offer an insightful review technical developments applications biomedicine over past 5 years. We focus on profound contributions profiling disease spectra, discovering new biomarkers, identifying promising drug targets, deciphering alterations conformation, unearthing protein–protein interactions. Moreover, summarize cutting‐edge potential breakthroughs pipeline principal challenges proteomics. Based these, aspire broaden applicability inspire researchers enhance our understanding complex systems by utilizing such techniques.
Язык: Английский
Процитировано
2
Genes & Diseases, Год журнала: 2022, Номер 10(3), С. 960 - 989
Опубликована: Авг. 23, 2022
Continuous revision of the histologic and stage-wise classification lung cancer by World Health Organization (WHO) provides foundation for therapeutic advances promoting molecular targeted immunotherapies ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information prevention, diagnosis, management, supporting health-care interventions. Global mortality projections from 2016 to 2060 show that will overtake ischemic heart diseases (IHD) as leading cause death (18.9 million) immediately after 2030, surpassing non-small cell (NSCLC), which accounts 85 percent cancers. The clinical stage at diagnosis is main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential initial stages reduced compared advanced stages. Sophisticated approaches proper histological management have improved efficiency. Although immune checkpoint inhibitors (ICIs) therapies refined late-stage NSCLC, specificity sensitivity biomarkers should be focusing on prospective studies, followed their use tools. liquid biopsy candidates such circulating tumor cells (CTCs), cell-free DNA (cfDNA), educated platelets (TEP), extracellular vesicles (EVs) possess cancer-derived biomolecules aid tracing: driver mutations cancer, acquired resistance caused various generations agents, refractory disease, prognosis, surveillance.
Язык: Английский
Процитировано
66
Small, Год журнала: 2022, Номер 18(42)
Опубликована: Авг. 26, 2022
Abstract Nowadays, artificial intelligence (AI) creates numerous promising opportunities in the life sciences. AI methods can be significantly advantageous for analyzing massive datasets provided by biotechnology systems biological and biomedical applications. Microfluidics, with developments controlled reaction chambers, high‐throughput arrays, positioning systems, generate big data that is not necessarily analyzed successfully. Integrating microfluidics pave way both experimental analytical throughputs research. Microfluidics enhances reduces cost scale, while improve analysis of huge obtained from multiplexed microfluidics. This review briefly presents a survey role biotechnology. Also, incorporation comprehensively investigated. Specifically, recent studies perform flow cytometry cell classification, isolation, combination them gaining microfluidic techniques are covered. Despite all current challenges, various fields remarkably affected technologies. Some these include point‐of‐care precision, personalized medicine, regenerative prognostics, diagnostics, treatment oncology non‐oncology‐related diseases.
Язык: Английский
Процитировано
51